News and Publications

Penningtons Manches Cooper acts for Stanford Capital and SI Capital on £6.5m equity fundraising

Posted: 03/09/2020


The corporate team at Penningtons Manches Cooper is advising Stanford Capital and SI Capital as joint brokers to ImmuPharma plc on a £6.5 million equity placing of new ordinary shares.

ImmuPharma is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. Its portfolio includes novel peptide therapeutics for autoimmune diseases, anti-infectives, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of systemic lupus erythematosus (lupus / SLE).

Admission of the new shares is expected to occur on 7 September 2020.

London-based corporate partner, Seb Orton, is leading on this deal with assistance from associate Hannah Shamsolmaali.


Return to news headlines

Penningtons Manches Cooper LLP

Penningtons Manches Cooper LLP is a limited liability partnership registered in England and Wales with registered number OC311575 and is authorised and regulated by the Solicitors Regulation Authority.

Penningtons Manches Cooper LLP